DOJOLVI is the first and only FDA-approved prescription treatment for long-chain fatty oxidation disorders (LC-FAOD)

UltraCare: Assistance in Gaining Access to DOJOLVI (TRIHEPTANOIN)

DOJOLVI is the first and only FDA-approved prescription treatment for long-chain fatty oxidation disorders (LC-FAOD)

Enroll by downloading the DOJOLVI start form

Fill out the form with your healthcare provider and fax it to 1-415-723-7474. Please note that a completed form is required for your enrollment. For additional support, please call 1-888-756-8657. 1-888-756-8657.

Learn about UltraCare 
Patient Services 

Our programs help facilitate access to our treatments.

Meet our 
UltraCare Guides 

Our dedicated team of specialists is ready to support you Monday-Friday, 6:00 AM-5:00 PM PT.

Stay informed and get the latest information 

Complete and submit the form to receive additional Ultragenyx educational materials.

LESS

What is DOJOLVI?

DOJOLVI is a prescription medicine used to treat long-chain fatty acid oxidation disorders (LC-FAOD) in children and adults.

Important Safety Information

What are the possible side effects of DOJOLVI?

  • Feeding tube problems. Feeding tubes may not work as well or stop working over time when taking DOJOLVI. Do not use DOJOLVI in feeding tubes made of polyvinyl chloride (PVC), a solid plastic material. Monitor the feeding tube to make sure it is working properly.
  • Intestinal absorption problems in patients with pancreatic insufficiency. If you have pancreatic insufficiency, consult with your healthcare provider as it may affect how well DOJOLVI works.
  • The most common side effects of DOJOLVI are:
    • stomach (abdominal) pain
    • vomiting
    • diarrhea
    • diarrhea
    • vomiting
    • nausea

These are not all the possible side effects of DOJOLVI. Call your healthcare provider for medical advice about side effects. You may report side effects to Ultragenyx Pharmaceutical Inc. at 1-888-756-8657 or FDA at 1-800-FDA-1088.

Before taking DOJOLVI, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. It is not known if DOJOLVI will harm your unborn baby. Pregnancy Safety Study: There is a pregnancy safety study for women who take DOJOLVI during pregnancy. The purpose of this study is to collect information about your health and your baby’s health. You can talk to your healthcare provider or contact 1-888-756-8657 to enroll in this study or get more information.
  • are breastfeeding or plan to breastfeed. It is not known if DOJOLVI passes into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take DOJOLVI.
  • are taking a pancreatic lipase inhibitor, such as orlistat, as it may affect how well DOJOLVI works.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take DOJOLVI?

  • See the detailed “Instructions for Use” at the end of the Patient Information Leaflet for instructions about how to mix and take DOJOLVI by mouth in soft foods or drinks or how to mix and give DOJOLVI through feeding tubes.
  • Take DOJOLVI exactly as your healthcare provider tells you.
  • Your healthcare provider may start you on a low dose of DOJOLVI and slowly increase your dose to help avoid side effects. If you are taking another medium chain triglyceride (MCT) product, stop taking the MCT before starting DOJOLVI.

Please see full Prescribing Information, including the Patient Information Leaflet, for additional Important Safety Information.

What is DOJOLVI?

DOJOLVI is a prescription medicine used to treat long-chain fatty acid oxidation disorders (LC-FAOD) in children and adults.

Important Safety Information

What are the possible side effects of DOJOLVI?

  • Feeding tube problems. Feeding tubes may not work as well or stop working over time when taking DOJOLVI. Do not use DOJOLVI in feeding tubes made of polyvinyl chloride (PVC), a solid plastic material. Monitor the feeding tube to make sure it is working properly.
  • Intestinal absorption problems in patients with pancreatic insufficiency. If you have pancreatic insufficiency, consult with your healthcare provider as it may affect how well DOJOLVI works.
  • The most common side effects of DOJOLVI are:
    • stomach (abdominal) pain
    • vomiting
    • diarrhea
    • diarrhea
    • vomiting
    • nausea

These are not all the possible side effects of DOJOLVI. Call your healthcare provider for medical advice about side effects. You may report side effects to Ultragenyx Pharmaceutical Inc. at 1-888-756-8657 or FDA at 1-800-FDA-1088.

Before taking DOJOLVI, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. It is not known if DOJOLVI will harm your unborn baby. Pregnancy Safety Study: There is a pregnancy safety study for women who take DOJOLVI during pregnancy. The purpose of this study is to collect information about your health and your baby’s health. You can talk to your healthcare provider or contact 1-888-756-8657 to enroll in this study or get more information.
  • are breastfeeding or plan to breastfeed. It is not known if DOJOLVI passes into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take DOJOLVI.
  • are taking a pancreatic lipase inhibitor, such as orlistat, as it may affect how well DOJOLVI works.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take DOJOLVI?

  • See the detailed “Instructions for Use” at the end of the Patient Information Leaflet for instructions about how to mix and take DOJOLVI by mouth in soft foods or drinks or how to mix and give DOJOLVI through feeding tubes.
  • Take DOJOLVI exactly as your healthcare provider tells you.
  • Your healthcare provider may start you on a low dose of DOJOLVI and slowly increase your dose to help avoid side effects. If you are taking another medium chain triglyceride (MCT) product, stop taking the MCT before starting DOJOLVI.

Please see full Prescribing Information, including the Patient Information Leaflet, for additional Important Safety Information.

For additional information and questions about medical information or medical affairs, please contact Ultragenyx Medical Affairs at 1-888-756-8657.